J
Janis Racevskis
Researcher at Albert Einstein College of Medicine
Publications - 24
Citations - 4333
Janis Racevskis is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Leukemia & Population. The author has an hindex of 16, co-authored 22 publications receiving 3674 citations. Previous affiliations of Janis Racevskis include New York Medical College & Montefiore Medical Center.
Papers
More filters
Journal ArticleDOI
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia
Jay P. Patel,Mithat Gonen,Maria E. Figueroa,Hugo Fernandez,Zhuoxin Sun,Janis Racevskis,Pieter Van Vlierberghe,Igor Dolgalev,Sabrena Thomas,Olga Aminova,Kety Huberman,Janice Cheng,Agnes Viale,Nicholas D. Socci,Adriana Heguy,Athena M. Cherry,Gail H. Vance,Rodney R. Higgins,Rhett P. Ketterling,Robert E. Gallagher,Mark R. Litzow,Marcel R.M. van den Brink,Hillard M. Lazarus,Jacob M. Rowe,Selina M. Luger,Adolfo A. Ferrando,Elisabeth Paietta,Martin S. Tallman,Ari Melnick,Omar Abdel-Wahab,Ross L. Levine +30 more
TL;DR: Genetic predictors of outcome that improved risk stratification among patients with AML, independently of age, white-cell count, induction dose, and post-remission therapy, are identified and the significance of these predictors in an independent cohort is validated.
Journal ArticleDOI
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Hugo F. Fernandez,Zhuoxin Sun,Xiaopan Yao,Mark R. Litzow,Selina M. Luger,Elisabeth Paietta,Janis Racevskis,Gordon W. Dewald,Rhett P. Ketterling,John M. Bennett,Jacob M. Rowe,Hillard M. Lazarus,Martin S. Tallman +12 more
TL;DR: In young adults with AML, intensifying induction therapy with a high daily dose of daunorubicin improved the rate of complete remission and the duration of overall survival, as compared with the standard dose.
Journal ArticleDOI
PAX5 -driven subtypes of B-progenitor acute lymphoblastic leukemia
Zhaohui Gu,Michelle L. Churchman,Kathryn G. Roberts,Ian Moore,Xin Zhou,Joy Nakitandwe,Kohei Hagiwara,Stephane Pelletier,Sebastien Gingras,Hartmut Berns,Debbie Payne-Turner,Ashley Hill,Ilaria Iacobucci,Lei Shi,Stanley Pounds,Cheng Cheng,Deqing Pei,Chunxu Qu,Scott Newman,Meenakshi Devidas,Yunfeng Dai,Shalini C. Reshmi,Julie M. Gastier-Foster,Elizabeth A. Raetz,Michael J. Borowitz,Brent L. Wood,William L. Carroll,Patrick A. Zweidler-McKay,Karen R. Rabin,Leonard A. Mattano,Kelly W. Maloney,Alessandro Rambaldi,Orietta Spinelli,Jerald P. Radich,Mark D. Minden,Jacob M. Rowe,Selina M. Luger,Mark R. Litzow,Martin S. Tallman,Janis Racevskis,Yanming Zhang,Ravi Bhatia,Jessica Kohlschmidt,Krzysztof Mrózek,Clara D. Bloomfield,Wendy Stock,Steven M. Kornblau,Hagop M. Kantarjian,Marina Konopleva,Williams E. Evans,Sima Jeha,Ching-Hon Pui,Jun J. Yang,Elisabeth Paietta,James R. Downing,Mary V. Relling,Jinghui Zhang,Mignon L. Loh,Stephen P. Hunger,Charles G. Mullighan +59 more
TL;DR: Analysis of 1,988 cases of B-cell acute lymphoblastic leukemia characterizes 23 subtypes defined by genomic features and shows that two of the subtypes have frequent PAX5 alterations, demonstrating the utility of transcriptome sequencing to classify B-ALL.
Journal ArticleDOI
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Gannie Tzoneva,Arianne Perez-Garcia,Zachary Carpenter,Hossein Khiabanian,Valeria Tosello,Maddalena Allegretta,Elisabeth Paietta,Janis Racevskis,Jacob M. Rowe,Jacob M. Rowe,Martin S. Tallman,Maddalena Paganin,Giuseppe Basso,Jana Hof,Renate Kirschner-Schwabe,Teresa Palomero,Raul Rabadan,Adolfo A. Ferrando +17 more
TL;DR: A prominent role for activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and chemotherapy resistance in ALL is supported.
Journal ArticleDOI
Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia
Erich Piovan,Erich Piovan,Jiyang Yu,Valeria Tosello,Daniel Herranz,Alberto Ambesi-Impiombato,Ana Carolina Da Silva,Marta Sanchez-Martin,Arianne Perez-Garcia,Isaura Rigo,Mireia Castillo,Stefano Indraccolo,Justin R. Cross,Elisa de Stanchina,Elisabeth Paietta,Elisabeth Paietta,Janis Racevskis,Janis Racevskis,Jacob M. Rowe,Martin S. Tallman,Giuseppe Basso,Jules P.P. Meijerink,Carlos Cordon-Cardo,Andrea Califano,Adolfo A. Ferrando +24 more
TL;DR: It is demonstrated that loss of PTEN and consequent AKT1 activation can effectively block glucocorticoid-induced apoptosis and induce resistance to glucoc Corticoid therapy, and pharmacologic inhibition of AKT with MK2206 effectively reverses glucocORTicoid resistance.